MT Newswires After-Hours News Movers
5:52PM ET 8/07/2019 MT NewswiresSome of the stocks moving on news-driven events in Wednesday's after-hours include: BKNG, +5.1% AVDR, +20.16% CVNA, +15.73% STMP, +15.52% SYMC, +12.93%...
Quotes Snapshot > SGMO
Sangamo Therapeutics Inc SGMO:NASDAQ
Last Price$11.35NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/16/19
Today's Change0(0.00%)
Bid (Size)$10.95 (3)
Ask (Size)$11.84 (5)
Day Low / HighN/A - N/A
Volume1.3 M
Read more news Recent News
Sangamo Therapeutics Q2 Loss Widens, Revenue Decreases But Tops Street Views
4:09PM ET 8/07/2019 MT NewswiresSangamo Therapeutics (SGMO) reported a net loss of $0.26 per share in Q2, wider than the year-earlier loss of $0.17 a share but narrower than the loss of...
Close Update: US Stocks Slide as Strong US Jobs Report Dampens Investor Hopes for Steep Rate Cuts
4:19PM ET 7/08/2019 MT NewswiresMajor stock indexes closed lower Monday as investor hopes for interest rate cuts at the end of July faded following June's strong employment report on...
Sector Update: Health Care Stocks Close Near Session Lows
4:03PM ET 7/08/2019 MT NewswiresTop Health Care Stocks JNJ +0.26% PFE -1.33% ABT -0.34% MRK -1.79% AMGN -1.98% Health care stocks retreated Monday, with the NYSE Health Care Index...
View all Commentary and Analysis
Sangamo: Lead Gene Therapy Program Moving Into Phase 3
5:45PM ET 8/13/2019 Seeking AlphaSangamo Therapeutics, Inc. 2019 Q2 - Results - Earnings Call Slides
1:47PM ET 8/13/2019 Seeking AlphaSangamo Therapeutics (SGMO) CEO Sandy Macrae on Q2 2019 Results - Earnings Call Transcript
12:47PM ET 8/13/2019 Seeking AlphaCompanies In The Healthcare Sector To Consider/Avoid Taking Into Account Patent Activity
2:59PM ET 8/07/2019 Seeking AlphaCompany Profile
Business DescriptionSangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA. View company web site for more details
| Address | Point Richmond Tech Center II Richmond, California 94804 |
| Phone | +1.510.970.6000 |
| Number of Employees | 302 |
| Recent SEC Filing | 08/14/2019 4 |
| President, Chief Executive Officer & Director | Alexander D. Macrae |
| Chief Financial Officer, EVP-Corporate Strategy | Stéphane Boissel |
| Chief Technology Officer & Senior Vice President | Edward J. Rebar |
| Executive Vice President & General Counsel | Gary H. Loeb |
Company Highlights
| Price Open | $11.13 |
| Previous Close | $11.05 |
| 52 Week Range | $6.26 - 19.25 |
| Market Capitalization | $1.3 B |
| Shares Outstanding | 115.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/14/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.99 |
| Beta vs. S&P 500 | N/A |
| Revenue | $84.5 M |
| Net Profit Margin | -136.73% |
| Return on Equity | -27.35% |
Analyst Ratings as of 08/09/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |